Coya Therapeutics, Inc., (Coya), a clinical-stage biotechnology company developing first-in-class approaches that utilize autologous regulatory T cells (Tregs) and allogeneic exosome therapeutics with a focus on neurodegenerative and autoimmune diseases, today announced that it has concurrently completed a merger with Nicoya Health, Inc. and raised $10 million in Series A financing from institutional and accredited investors. The merger and financing, which include conversion of outstanding debt, was led by Allele Capital Partners LLC.
Read the full article: Coya Therapeutics Completes Merger with Nicoya Health Inc. //
Source: https://www.globenewswire.com/news-release/2021/02/03/2168937/0/en/Coya-Therapeutics-Completes-Merger-with-Nicoya-Health-Inc-and-Announces-10-Million-Series-A-Financing-to-Advance-Pipeline-of-Regulatory-T-cell-Therapeutics-Optimized-for-Neurodegen.html